Related Experiment Videos

Defibrotide decreases cholesterol amount in hypercholesterolemic rabbit aorta, with no modification of plasma or

R Pescador1, R Porta, A Conz

  • 1Crinos Biological Research Laboratories, Villa Guardia Como, Italy.

Life Sciences
|January 1, 1989
PubMed

Insights

Defibrotide, an antithrombotic agent, reduced aortic cholesterol and vascular lesions in rabbits. This suggests defibrotide

Area of Science:

  • Cardiovascular Science
  • Pharmacology

Background:

  • Atherosclerosis involves cholesterol deposition and vascular lesions.
  • Antithrombotic agents may influence atherosclerotic processes.

Purpose of the Study:

  • To investigate the effect of defibrotide on cholesterol levels and vascular lesions in a rabbit model of atherosclerosis.
  • To explore the potential role of defibrotide's antithrombotic activity in managing cardiovascular conditions.

Main Methods:

  • Cholesterol-fed rabbits received intravenous defibrotide or placebo.
  • Measurements included aortic cholesterol, plasma lipids, platelet aggregation, and vascular lesion counts.

Main Results:

  • Defibrotide decreased aortic cholesterol and reduced platelet aggregation.
  • Fewer vascular lesions were observed in defibrotide-treated rabbits compared to placebo.
  • Plasma lipid profiles and lipoprotein composition remained unchanged.

Conclusions:

  • Defibrotide demonstrates potential in reducing cholesterol accumulation in the aorta.
  • Its antithrombotic properties may mitigate vascular damage in atherosclerosis-prone states.
  • Defibrotide's ability to decrease platelet sensitivity is a key factor in its cardiovascular benefits.

Related Concept Videos